ArticleMycopathologia2025
Diagnostic Potential of a Recombinant Candida albicans Hyr1 Protein.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Invasive candidiasis (IC) is a life-threatening fungal infection caused by Candida species. Current diagnostic methods are based on blood culture of the fungus, a technique with limited sensitivity and slow turnaround times. To address these limitations, novel diagnostic strategies are under investigation. This study evaluates the diagnostic potential of the Candida albicans germ tube protein Hyr1 and a subterminal Hyr1 fragment (D22b), both produced in an eukaryotic expression system, for the diagnosis of IC; for that purpose, recombinant Hyr1 and D22b were expressed in Pichia pastoris and tested by ELISA using sera from 176 patients at risk of invasive fungal infections. The diagnostic performance of these antigens was determined and compared with other biomarkers (CAGTA and β-D-glucan). Interestingly, the recombinant proteins exhibited higher apparent molecular weights than predicted, suggesting the presence of post-translational modifications. Serological detection of antibodies against the recombinant Hyr1 and D22b fragment successfully distinguished patients with IC caused by the most commonly isolated Candida species, achieving sensitivities greater than 70% and specificities above 80%. These findings highlight the potential of the serological detection of antibodies to Hyr1 and D22b as a promising diagnostic approach that overcomes the drawbacks of CAGTA detection and could serve as a valuable complement to blood culture, supporting earlier diagnosis and guiding timely treatment decisions in IC. Furthermore, comparing results obtained with antigens produced in eukaryotic and prokaryotic systems, results suggest that accurate protein folding and post-translational processing influence the success of the diagnostic technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.